United States Patent 12,453,755 (tirzepatide diabetes): scope, claim-by-claim boundaries, and US patent landscape
Scope of US Patent 12,453,755: what exactly is claimed and what is excluded?
US Patent 12,453,755 is directed to a method of treating diabetes using a tirzepatide (or pharmaceutically acceptable salt) pharmaceutical composition defined by tight concentration ranges for three excipient components plus optional phenol, and (in dependent claims) pH and administration modality (automatic injection; once weekly).
Core claim structure (independent claim set)
- Claim 1 is the broadest you provided. It ties diabetes treatment to administering a composition having:
- Tirzepatide (or salt): 5 to 30 mg/mL
- Dibasic sodium phosphate: 0.67 to 2.68 mg/mL
- NaCl: 6.2 to 9.5 mg/mL
- Optional phenol: 3.0 to 7.0 mg/mL
- Claim 4 is a second independent claim you provided, narrower than claim 1 because it removes optional phenol and fixes the excipient set to:
- Tirzepatide: 5 to 30 mg/mL (via claim 5)
- NaCl: 6.2 to 9.5 mg/mL
- Dibasic sodium phosphate: not range-fixed in claim 4, but constrained in dependent claims 6-8
What the claim language does not capture
Based on the claim text supplied:
- There is no claim to:
- specific device architecture except via the “automatic injection apparatus” limitation (claim 2)
- molecular modifications of tirzepatide (sequence/salt identity is not spelled out beyond “pharmaceutically acceptable salt”)
- additional excipients beyond phenol being optionally present in claim 1
- manufacturing process parameters
- There is no free-form “composition comprising” for excipients other than the listed components. Courts typically interpret “comprising” to allow additional ingredients, but the infringement hinge is whether the accused product includes at least the claimed components at concentrations within the recited ranges.
Claim-by-claim scope map: concentration ranges, pH limits, and device/timing requirements
How do claims 1, 4, and dependent claims constrain infringement?
The concentration ranges create the principal infringement boundary: if a proposed tirzepatide product has different NaCl or dibasic sodium phosphate concentrations outside the recited bands, it can fall outside these claims.
Claim 1 (baseline method claim; widest)
Infringement requires:
- diabetes treatment in a human by administering the composition
- tirzepatide concentration 5 to 30 mg/mL
- dibasic sodium phosphate concentration 0.67 to 2.68 mg/mL
- NaCl concentration 6.2 to 9.5 mg/mL
- phenol optional only (presence is not required; if phenol is present it must be 3.0 to 7.0 mg/mL to read on claim 1’s stated phenol option)
Practical boundary: a generic/biosimilar formulation that matches tirzepatide concentration but shifts NaCl or phosphate concentration is an obvious design-around lever.
Claim 2 (device limitation)
Adds:
- administration using an automatic injection apparatus
Practical boundary: if a product is delivered via non-automatic means, this dependent claim is not met. However, claim 1 could still be asserted if the composition matches without this limitation.
Claim 3 (frequency limitation)
Adds:
- dose administered once weekly
Practical boundary: only once-weekly regimens infringe claim 3 (if asserted as written). A different dosing interval could avoid claim 3 while still risking claim 1/4.
Claim 4 (second independent claim; removes phenol option)
Requires:
- tirzepatide (or salt)
- NaCl within 6.2 to 9.5 mg/mL
- dibasic sodium phosphate (not range stated in claim 4, but is limited in dependent claims 6-8)
Claim 4’s scope relative to claim 1:
- It keeps the same NaCl band and tirzepatide range via dependent claims
- It does not include the explicit phenol option
Claims 5-9 (tightening by fixing subranges and discrete concentration values)
- Claim 5: tirzepatide concentration 5 to 30 mg/mL (reinforces claim 1’s range)
- Claims 6-8: dibasic sodium phosphate:
- claim 6: 1 to 3 mg/mL
- claim 7: 0.67 to 2.68 mg/mL
- claim 8: about 1.34 mg/mL (single point)
- Claim 9: tirzepatide concentration is one of discrete values:
- 5, 10, 15, 20, 25, 30 mg/mL
Practical boundary:
- If the product uses a tirzepatide concentration not in the discrete set, it avoids claim 9 specifically, but may still infringe claim 1/5/12 depending on whether it stays within the broader continuous range.
- The single-point phosphate value in claim 8 is a strong discriminator: matching formulation exactly at ~1.34 mg/mL dibasic sodium phosphate is required for that dependent claim.
Claims 10-12 (NaCl and discrete tirzepatide selection)
- Claim 10: NaCl 7.0 to 9.0 mg/mL
- Claim 11: NaCl about 8.2 mg/mL
- Claim 12: tirzepatide concentration is one of:
- 5, 10, 15, 20, 25, 30 mg/mL
These create “stacked” dependent claim pathways. If an accused product lands on the about 8.2 mg/mL NaCl and ~1.34 mg/mL phosphate points while using the discrete tirzepatide concentrations, it reads on multiple dependent claims simultaneously.
Claim 13 (pH limitation)
- composition pH 6.5 to 7.5
Claim 14 (most specific embodiment of a composition)
Adds all of the following concurrently:
- tirzepatide: 5 to 30 mg/mL
- dibasic sodium phosphate: about 1.34 mg/mL
- NaCl: about 8.2 mg/mL
- pH 6.5 to 7.5
This is the tightest claim in the set you provided. It functions like an “embodiment lock” around a specific formulation profile.
What formulation differences would likely avoid infringement?
Using the claim boundaries as design constraints:
NaCl design-around
- Avoid the bands in claim 1/4:
- 6.2 to 9.5 mg/mL (claim 1/4)
- Also avoid narrower dependent bands if targeting those:
- 7.0 to 9.0 mg/mL (claim 10)
- about 8.2 mg/mL (claim 11)
Dibasic sodium phosphate design-around
- Avoid:
- 0.67 to 2.68 mg/mL (claim 1/7)
- 1 to 3 mg/mL (claim 6)
- about 1.34 mg/mL (claim 8)
Because these bands overlap, a formulation must move outside the entire overlapping capture ranges to reduce risk across dependent claim paths.
pH design-around
- Avoid pH 6.5 to 7.5 (claims 13 and 14), if seeking to avoid those dependent claims.
Device/timing design-around
- Avoid “automatic injection apparatus” (claim 2) and “once weekly” (claim 3) to defeat those dependent claims, though the underlying composition claims (1/4 and concentration-based dependents) remain.
Relationship to tirzepatide commercial products: how these claims map to real-world dosing
Tirzepatide’s marketed regimen is typically once weekly delivered via pen/auto-injector formats. If the accused product uses a similar administration approach, claims 2 and 3 become easier to satisfy for the claimant.
However, infringement is not just about regimen; it hinges on whether the administered formulation matches the excipient concentration ranges and pH. That makes formulation reformulation the primary shield against claim coverage.
How strong is the patent estate around US 12,453,755 based on the claim posture?
Even without reviewing additional claims beyond the ones you supplied, the claim posture suggests:
- The patent is not a broad “tirzepatide for diabetes” monopoly.
- It is a formulation-and-administration-limited method claim anchored to specific excipient concentration ranges (phosphate and NaCl), a phenol presence option, pH, and device/timing in dependent layers.
Litigation posture implications
- If asserted, it would likely be tested on:
- accused product composition analytics (NaCl, dibasic sodium phosphate, phenol presence/amount, pH)
- dosing regimen proof (once weekly for claim 3)
- delivery method proof (automatic injection for claim 2)
- The strongest infringement case is where the accused tirzepatide product matches:
- phosphate near 1.34 mg/mL
- NaCl near 8.2 mg/mL
- pH 6.5 to 7.5
- delivered using the relevant injector and regimen
US patent landscape context: where a formulation-limited tirzepatide method claim fits
US 12,453,755’s scope sits inside a typical US tirzepatide patent landscape where:
- “composition/formulation” claims often create later-life protection for excipients, pH, and delivery-ready presentations
- “method of use” claims often track dosing regimens and administration devices
- “therapeutic” and “molecule” level claims (if present) control the earliest exclusivity window, while formulation and device add-ons protect specific marketed presentation choices
Within that ecosystem, US 12,453,755 is best characterized as a presentation-level method claim: it does not expand beyond tirzepatide diabetes treatment, but it constrains infringement through measurable formulation parameters.
How would generic entry or Paragraph IV challenges be evaluated against this patent?
For an ANDA-style challenge (or a biosimilar/generic-equivalent strategy depending on regulatory status), the most relevant evaluation items against this patent are:
Product matching checklist (infringement-to-noninfringement analysis)
- Tirzepatide concentration: within 5–30 mg/mL
- Dibasic sodium phosphate: outside 0.67–2.68 mg/mL (or outside 1–3 mg/mL) if possible
- NaCl: outside 6.2–9.5 mg/mL
- Phenol: avoid the specific presence/amount band 3.0–7.0 mg/mL if relying on phenol as the optional anchor
- pH: outside 6.5–7.5
- Device and regimen: avoid “automatic injection” and/or “once weekly” if possible
Noninfringement leverage
Because the claim uses concentration ranges, a challenger can attempt:
- formulation re-specification (excipient swaps or concentration shifts)
- pH shift
- change in device/regimen (only attacks dependent claims unless it also affects how the product is administered)
Licensing and settlement risk signals implied by the claim structure
Formulation concentration claims often drive settlement because:
- the claimant can test actual samples and analytic specifications
- the dependent claims (8, 11, 14) create “exact-point” infringement pathways
- resolution can be tied to product design modifications or authorized formulation specs
This claim set is particularly suited to settlement because it is parameterized in a way that can be validated quickly through chemistry and label/spec sheet alignment.
What generic launch scenarios have the highest risk under these claims?
Highest risk scenarios are those where the accused product:
- matches tirzepatide concentration within 5–30 mg/mL
- uses NaCl and dibasic sodium phosphate concentrations near the central “about” points:
- about 8.2 mg/mL NaCl
- about 1.34 mg/mL dibasic sodium phosphate
- maintains pH in 6.5–7.5
- is delivered using an automatic injection apparatus
- is dosed once weekly
Key takeaways
- US Patent 12,453,755 is a tirzepatide-for-diabetes method patent that is formulation-limited to measurable excipient concentration bands for dibasic sodium phosphate and NaCl, with optional phenol plus pH in dependent claims.
- The tightest coverage is in claim 14, which requires a specific excipient profile (~1.34 mg/mL phosphate, ~8.2 mg/mL NaCl) and pH 6.5–7.5, alongside tirzepatide 5–30 mg/mL.
- Dependent claims narrow by administration device (“automatic injection apparatus”) and dosing frequency (“once weekly”).
- The most direct design-around levers are shifting NaCl/phosphate concentrations outside the claimed ranges and moving pH outside 6.5–7.5, while device/regimen changes primarily affect dependent claim coverage.
FAQs
1) What is the main infringement trigger in US 12,453,755?
Matching the administered tirzepatide composition to the claimed NaCl and dibasic sodium phosphate concentrations (and, in some dependents, pH), for treating diabetes in a human.
2) Does US 12,453,755 cover tirzepatide even if phenol is absent?
Yes, phenol is optional in claim 1. If phenol is absent, claim 1 can still be met if other composition parameters match.
3) Which dependent claims require “about” specific concentrations?
Claim 8 requires dibasic sodium phosphate about 1.34 mg/mL and claim 11 requires NaCl about 8.2 mg/mL; claim 14 combines both plus pH.
4) Can a different tirzepatide concentration avoid claim 9/12?
Yes. Claim 9 and claim 12 limit tirzepatide to discrete values (5, 10, 15, 20, 25, 30 mg/mL). Concentrations outside that set avoid those dependent claims if other elements are met.
5) How do device and dosing interval limitations affect risk?
Claim 2 adds “automatic injection apparatus” and claim 3 adds “once weekly.” These are only relevant to those dependent claims, while claims 1 and 4 remain driven by the composition parameters.